<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Transcriptional persistence programs &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/transcriptional-persistence-programs/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 06 Nov 2025 16:46:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Transcriptional persistence programs &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Uncovering a Crucial Cellular Mechanism Behind Breast Cancer Relapse</title>
		<link>https://bioengineer.org/uncovering-a-crucial-cellular-mechanism-behind-breast-cancer-relapse/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 06 Nov 2025 16:46:09 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Drug resistance mechanisms]]></category>
		<category><![CDATA[FOSL1 regulatory protein]]></category>
		<category><![CDATA[Persister cells]]></category>
		<category><![CDATA[Transcriptional persistence programs]]></category>
		<category><![CDATA[Triple-negative breast cancer relapse]]></category>
		<guid isPermaLink="false">https://bioengineer.org/uncovering-a-crucial-cellular-mechanism-behind-breast-cancer-relapse/</guid>

					<description><![CDATA[Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in oncology due to its aggressive nature and its notorious resistance to conventional treatment modalities. Unlike other breast cancer subtypes, TNBC lacks expression of estrogen receptor, progesterone receptor, and HER2, rendering many targeted therapies ineffective. While initial chemotherapy regimens often induce a significant reduction [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">292719</post-id>	</item>
	</channel>
</rss>
